

# Curated PubMed Collection

Direct Links to Peer-Reviewed Research

This collection provides direct access to peer-reviewed abstracts and full papers on ibogaine research. Each entry includes the PubMed link for easy access to the abstract, citation tools, and related articles. Many papers offer free full-text access through PubMed Central or publisher open-access policies.

## How to Use This Collection

1. Click any PubMed link to view the abstract and publication details
2. Look for 'Free PMC article' or 'Free full text' buttons for open access papers
3. Use the 'Cite' button on PubMed to export citations in any format
4. Check 'Similar articles' on PubMed to discover related research

Prepared by Iboga Healing Portugal

## Landmark Studies

### **Magnesium-ibogaine therapy in veterans with traumatic brain injuries**

Cherian KN, Keynan JN, Anker L, et al. — *Nature Medicine*, 2024; 30(2):373-381

PubMed: <https://pubmed.ncbi.nlm.nih.gov/38182784/>

### **Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes**

Brown TK, Alper K — *The American Journal of Drug and Alcohol Abuse*, 2018; 44(1):24-36

PubMed: <https://pubmed.ncbi.nlm.nih.gov/28910152/>

### **Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up**

Noller GE, Frampton CM, Yazar-Klosinski B — *The American Journal of Drug and Alcohol Abuse*, 2018; 44(1):37-46

PubMed: <https://pubmed.ncbi.nlm.nih.gov/28910151/>

## Addiction Treatment

### **Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence**

Mash DC, Duque L, Page B, Allen-Ferdinand K — *Frontiers in Pharmacology*, 2018; 9:529

PubMed: <https://pubmed.ncbi.nlm.nih.gov/29881351/>

### **Treatment of acute opioid withdrawal with ibogaine**

Alper KR, Lotsof HS, Frenken GM, et al. — *The American Journal on Addictions*, 1999; 8(3):234-242

PubMed: <https://pubmed.ncbi.nlm.nih.gov/10506904/>

### **The ibogaine medical subculture**

Alper KR, Lotsof HS, Kaplan CD — *Journal of Ethnopharmacology*, 2008; 115(1):9-24

PubMed: <https://pubmed.ncbi.nlm.nih.gov/18029124/>

### **Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine**

Baumann MH, Pablo JP, Ali SF, et al. — *Annals of the New York Academy of Sciences*, 2000; 914:354-368

PubMed: <https://pubmed.ncbi.nlm.nih.gov/11085338/>

### **Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration**

Carnicella S, He DY, Yowell QV, et al. — *Addiction Biology*, 2010; 15(4):424-433

PubMed: <https://pubmed.ncbi.nlm.nih.gov/20624152/>

### **Ibogaine, an anti-addictive drug: pharmacology and time to go further in development**

Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V — *Human & Experimental Toxicology*, 2008; 27(3):181-194

PubMed: <https://pubmed.ncbi.nlm.nih.gov/18650249/>

### **New directions in the treatment of opioid withdrawal**

Srivastava AB, Mariani JJ, Levin FR — *The Lancet*, 2020; 395(10241):1938-1948

PubMed: <https://pubmed.ncbi.nlm.nih.gov/32563380/>

## Neuroplasticity & Growth Factors

### **Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits**

Marton S, González B, Rodríguez-Bottero S, et al. — *Frontiers in Pharmacology*, 2019; 10:193

PubMed: <https://pubmed.ncbi.nlm.nih.gov/30930775/>

### **Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of ibogaine**

He DY, Ron D — *FASEB Journal*, 2006; 20(13):2420-2422

PubMed: <https://pubmed.ncbi.nlm.nih.gov/17023519/>

### **Chronic heroin and cocaine abuse is associated with decreased serum concentrations of NGF and BDNF**

Angelucci F, Ricci V, Pomponi M, et al. — *Journal of Psychopharmacology*, 2007; 21(8):820-825

PubMed: <https://pubmed.ncbi.nlm.nih.gov/17715205/>

### **Intraventricular administration of BDNF increases newly generated neurons in the adult olfactory bulb**

Zigova T, Pencea V, Wiegand SJ, Luskin MB — *Molecular and Cellular Neurosciences*, 1998; 11(4):234-245

PubMed: <https://pubmed.ncbi.nlm.nih.gov/9675054/>

## Mechanisms of Action

### **The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters**

Bulling S, Schicker K, Zhang YW, et al. — *The Journal of Biological Chemistry*, 2012; 287(22):18524-18534

PubMed: <https://pubmed.ncbi.nlm.nih.gov/22451652/>

### **Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration**

Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW — *European Journal of Pharmacology*, 2002; 438(1-2):99-105

PubMed: <https://pubmed.ncbi.nlm.nih.gov/11906717/>

### **Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures**

Mash DC, Kovera CA, Pablo J, et al. — *Annals of the New York Academy of Sciences*, 2000; 914:394-401

PubMed: <https://pubmed.ncbi.nlm.nih.gov/11085341/>

## Mental Health & PTSD

### **Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans**

Davis AK, Averill LA, Sepeda ND, et al. — *Chronic Stress*, 2020; 4

PubMed: <https://pubmed.ncbi.nlm.nih.gov/32954002/>

### **Effects of low dose ibogaine on subjective mood state and psychological performance**

Forsyth B, Machado L, Jowett T, et al. — *Journal of Ethnopharmacology*, 2016; 189:10-13

PubMed: <https://pubmed.ncbi.nlm.nih.gov/27178633/>

**Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin**

*Mash DC, Staley JK, Baumann MH, et al. — Life Sciences, 1995; 57(3):PL45-PL50*

PubMed: <https://pubmed.ncbi.nlm.nih.gov/7596223/>

## Neurodegenerative Disease

### Treatment of Parkinson's disease with trophic factors

Peterson AL, Nutt JG — *Neurotherapeutics*, 2008; 5(2):270-280

PubMed: <https://pubmed.ncbi.nlm.nih.gov/18394569/>

### Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

Gill SS, Patel NK, Hotton GR, et al. — *Nature Medicine*, 2003; 9(5):589-595

PubMed: <https://pubmed.ncbi.nlm.nih.gov/12669033/>

### Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain

Love S, Plaha P, Patel NK, et al. — *Nature Medicine*, 2005; 11(7):703-704

PubMed: <https://pubmed.ncbi.nlm.nih.gov/16015352/>

### Regulation of natural cell death in dopaminergic neurons by striatal GDNF in vivo

Oo TF, Kholodilov N, Burke RE — *The Journal of Neuroscience*, 2003; 23(12):5141-5148

PubMed: <https://pubmed.ncbi.nlm.nih.gov/12832539/>

## Autoimmune & Inflammatory Conditions

### Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases

Jia J, Cheng J, Wang C, Zhen X — *Frontiers in Cellular Neuroscience*, 2018; 12:314

PubMed: <https://pubmed.ncbi.nlm.nih.gov/30283302/>

### High-affinity $\sigma$ 1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis

Oxombre B, Lee-Chang C, Duhamel A, et al. — *British Journal of Pharmacology*, 2015; 172(7):1769-1782

PubMed: <https://pubmed.ncbi.nlm.nih.gov/25409768/>

### Psychedelics as a novel approach to treating autoimmune conditions

Thompson C, Szabo A — *Immunology Letters*, 2020; 228:45-54

PubMed: <https://pubmed.ncbi.nlm.nih.gov/33039460/>

---

*This collection is provided for educational purposes only and does not constitute medical advice. PubMed is a service of the U.S. National Library of Medicine. Access to full-text articles may require institutional subscriptions.*